Author

E. Cortes-Sanchez

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:clustering· 2 Research Focus:differential expression· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:DNA methylation· 1

Frequent Co-Authors

C.-H. Yang· 3 shared A. L. Welm· 2 shared B. E. Welm· 2 shared K. P. Guillen· 2 shared S. D. Scherer· 2 shared X. Y. Woo· 2 shared A. Bertotti· 1 shared A. Butterfield· 1 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C.-H. Yang

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Multiparametric quantitative phase imaging for real-time, single cell, drug screening in breast cancer

E. R. Polanco, T. E. Moustafa, A. Butterfield, S. D. Scherer, E. Cortes-Sanchez, T. Bodily, B. T. Spike, B. E. Welm, P. S. Bernard, T. A. Zangle

This study uses multiparametric quantitative phase imaging to assess drug response in breast cancer cells, revealing single-cell heterogeneity and resistance dynamics.

bioRxiv · Nov 26, 2021Bioengineering

A breast cancer patient-derived xenograft and organoid platform for drug discovery and precision oncology

K. P. Guillen, M. Fujita, A. J. Butterfield, S. D. Scherer, M. H. Bailey, Z. Chu, Y. S. DeRose, L. Zhao, E. Cortes-Sanchez, C.-H. Yang, J. Toner, G. Wang, Y. Qiao, X. Huang, J. A. Greenland, , A. L. Welm

The paper develops patient-derived xenografts and organoids for breast cancer to enable drug screening and precision oncology, showing efficacy of an FDA-approved drug in a clinical case.

bioRxiv · Feb 28, 2021 · PreprintCancer Biology

PELP1/SRC-3-dependent regulation of metabolic kinases drives therapy resistant ER+ breast cancer

T. H. Truong, E. A. Benner, K. M. Hagen, N. A. Temiz, C. Perez Kerkvliet, Y. Wang, E. Cortes-Sanchez, C.-H. Yang, T. Pengo, K. P. Guillen, B. W. Welm, S. Telang, C. A. Lange, J. H. Ostrander

This study identifies PELP1/SRC-3-dependent regulation of metabolic kinases as a driver of therapy-resistant ER+ breast cancer and shows that targeting PFKFBs can block tumorsphere formation in resistant models.

bioRxiv · Aug 7, 2020Cancer Biology

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

X. Y. Woo, J. Giordano, A. Srivastava, Z.-M. Zhao, M. W. Lloyd, R. de Bruijn, Y.-S. Suh, R. Patidar, L. Chen, S. Scherer, M. Bailey, C.-H. Yang, E. Cortes-Sanchez, Y. Xi, J. Wang, , B. E Welm

This study shows that copy number profiles are conserved in patient-derived xenografts (PDXs) through engraftment and passaging, indicating minimal impact from the mouse host on tumor evolution.

bioRxiv · Dec 3, 2019Cancer Biology